inCVAX is a novel immunotherapy intended to treat solid metastatic cancers with potential to advance the standard of care. It is a therapeutic cancer vaccine intended to generate an immune response against the primary tumor and distant metastases. Significant reduction of tumor burden up to full resolution of the treated tumor and untreated distant metastases has been observed.

inCVAX is specific, systemic, and targeted:

inCVAX is Specific: It sources tumor antigens directly from the individual tumor. These antigens are patient and tumor unique.

inCVAX is Systemic: Administering inCVAX at a single site could potentially activate the immune system to target and fight metastases throughout the body.

inCVAX is Targeted: Activated T cells attack cancer cells. Initial research indicates, noncancerous tissues remain unaffected at selected dose.


N-dihydro-galacto-chitosan (GC) is a proprietary synthesized, stable, functionalized carbohydrate polymer that shows significant immune-stimulating effects. N-dihydro-galacto-chitosan is intended to enhance: antigen uptake by dendritic cells, cell maturation, IL-12 production, and stimulate macrophages. When administered with checkpoint inhibitors, in an animal model of metastatic melanoma, a synergy was observed that prolonged life.

How it Works

Immunophotonics therapy, inCVAX, combines a laser treatment with N-dihydro-galacto-chitosan to elicit a systemic anti-tumor immune response against the cancer. The inCVAX two-step procedure involves:

  1. stimulating an accessible tumor with laser energy to liberate whole-cell tumor antigens, followed by
  2. an injection of our proprietary drug, N-dihydro-galacto-chitosan into the laser-treated tumor, intended to induce a systemic immune response.